PDCD1 and cancer: This candidate therapeutic is currently being tested in a number of clinical trials including as a combination partner with anti-PD-1 ICB and a personalized cancer vaccine NEO-PV-01, consisting of up to 20 neoantigen peptides with adjuvanticity using Poly-ICLC, in patients with advanced melanoma (NCT03597282).